---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-054273"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2023-11-21T23:59:59+00:00"
generated_at: "2026-06-07T22:34:54.050242+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Femasys appoints Joshua Silverman to board in connection with private placement

## Summary
- Joshua Silverman appointed director effective Nov 21, 2023, nominated by PharmaCyte Biotech under board nomination right.
- Silverman serves as interim CEO, President and Director of PharmaCyte Biotech.
- He is independent director under Nasdaq rules and will serve on Nominating Committee.
- Term as Class II director until annual meeting following Dec 31, 2026; entitled to standard director compensation and indemnification.
- Appointment follows previously announced private placement of convertible notes and warrants closed Nov 21, 2023.

## SEC filing metadata
- accession: 0001140361-23-054273
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2023-11-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036123054273/0001140361-23-054273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036123054273/ef20015127_form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-054273
- JSON: https://secwatch.observer/filing/0001140361-23-054273.json
- Plain text: https://secwatch.observer/filing/0001140361-23-054273.txt

## Key facts
- Executive change
  Joshua Silverman was appointed as director at FEMASYS INC.
  - Action: appointed
  - Role: director
  source text: the Board of Directors (the “Board”) of Femasys Inc. (the “Company”) appointed Joshua Silverman as director of the Company effective November 21, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036123054273/0001140361-23-054273-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.